Anticoccidial Drugs Market Snapshot

“The Anticoccidial Drugs Market to grow from USD 1.42 Billion in 2023 to USD 1.97 Billion by 2030, at a CAGR of 3.6%.”

Anticoccidial drugs are commonly used as veterinary medications and feed additives to treat and prevent coccidiosis in poultry and other animals. Due to the severe economic impact of coccidiosis, most poultry farms use these medications as feed supplements for 12 to 16 weeks, and broiler birds for their entire lives.

Anticoccidial drugs are crucial for controlling poultry coccidiosis, focusing on specific stages of the parasite's life cycle. They can act coccidiostatic, halt Eimeria development, or both.

As clinical indications are not yet available, these drugs are recommended as a prophylactic approach, as they are too late to permanently stop the disease's effects.

The poultry industry utilizes various anticoccidial drugs, such as:

Ionophores

• This substance, produced through fermentation, functions as both a coccidiostat and a coccidiocide.
• Examples of monensin and lasalocid are a type of fungus that can be found in various types of plants.

Chemicals

• chemically generated synthetic substances
• Absent ionophores
• Examples consist of amprolium and decoquinate.

Key Insights

• Regulatory Scenario: For Important Nations
• New Product Launch
• Significant Industry Developments: Acquisitions, Mergers, and Collaborations

COVID-19 Impact on Global AntiCoccidial Drugs Market

The COVID-19 pandemic negatively impacted the global anti-coccidial medication market, leading to concerns among dog owners about a decline in pet disease diagnoses.

The early stages of the pandemic significantly impacted veterinarians, disrupting routine procedures like veterinary examinations, diagnosis, and surgery.

This reduced services hindered market expansion as coccidiosis diagnosis decreased, affecting the overall health of the pet population.

Segment Analysis

Segment by Drug Type

The companion animal segment is expected to grow significantly due to its increasing popularity and the region's advanced healthcare infrastructure, which is expected to contribute significantly to the anticoccidial medicine industry.

Merck & Co., Inc. reported that Isospora species is the most common cause of coccidiosis in dogs and cats, infecting nearly all cats at some point in their lives.

Young animals in high-population institutions are most susceptible to coccidiosis, making it a potential issue in breeding or boarding kennels and catteries. The prevalence of coccidiosis in companion animals presents a potential market for anticoccidial medications.

Segment by Drug Action

The Anticoccidial Drugs Market Size in 2022 was primarily dominated by the coccidiostatic segment due to increased research and adoption of coccidiostatic medicines.

This trend is expected to continue, with the growing preference for anti-coccidiosis medications for illness management contributing to market expansion. The coccidiostatic segment is expected to remain dominant in the Anticoccidial Drugs Market.

Growth Drivers

The growing number of people keeping animals is largely due to the favorable economic climate in developed economies. In 2022, 58% of British homes had pets, with pet owners being more concerned about their animals' safety. This awareness allows for the diagnosis of bacterial and fungal illnesses, such as coccidiosis, which is expected to contribute to the overall growth of the pet food market.

Pet owners are investing heavily in pet health insurance, increasing the cost of care and driving market expansion. As of 2021, 4.41 million pets in North America were covered by insurance. The American Pet Products Association reported a 123.6 billion US spending on pets and animals in 2021, up from 99.0 billion in 2020. This spending is expected to stimulate market growth over the forecast period.

Restraints

There are few studies and surveys available.

The market's expansion is hindered by a lack of research and surveys on this particular illness.

High medicine costs

The market's expansion is hindered by the high cost of anti-coccidial drugs, including polyether antibiotics, ionophores, and combination medications.

Opportunities

Coccidiosis is a prevalent disease in animals of specific age, necessitating the availability of anticoccidial medications. The Eimeria genus, which includes multiple species causing coccidiosis, affects various animals, including cats, dogs, cattle, poultry, and smaller ruminants like sheep and goats.

The presence of over 20 Eimeria species in bovine feces increases market expansion prospects.

Competitive Landscape of the Anticoccidial Drugs Market Analysis

Major players include Boehringer Ingelheim, Ceva, Elanco Animal Health, Merck, Virbac, and Zoetis.

New Developments in Anticoccidial Drugs Market

28 September 2023- Ceva’s Roberto Soares says treatment shift happening for coccidiosis

Dr. Roberto Soares, Global Marketing Manager at Ceva for the Coccidiosis portfolio of vaccines, spoke to The Poultry Site’s Sarah Mikesell at IPPE in Atlanta, Georgia, USA.

“Coccidiosis is one of the most important diseases for poultry,” said Dr. Soares. “It's caused by Eimeria, a parasite, which infects the intestinal tract of birds.”

Coccidiosis causes delays in growth, impacts feed conversion rate and uniformity. It also can increase mortality causing significant losses for the poultry producers and to the industry.

In August 2022, ZIVO Bioscience, Inc., a biotech/agtech R&D company, received a letter from the United States Department of Agriculture’s (USDA) Center for Veterinary Biologics (CVB) affirming that the agency has claimed jurisdiction to review the company’s novel immune-modulating biologic for treating coccidiosis in broiler chickens.

In March 2022, Amlan International launched two new natural alternatives to antibiotics for poultry and livestock, such as Phylox Feed and NeutraPath. Phylox Feed is a natural alternative to anticoccidial drugs and vaccines that can help producers increase profitability.

Regional Analysis of Global Anticoccidial Drugs Industry

North America currently dominates the anticoccidial medication market, driven by increased animal adoption and per-capita spending on animal healthcare.

The US pet adoption trend is expected to fuel market expansion, with nearly 70% of households owning a pet, or 90.5 million houses total. The demand for anticoccidial medications is expected to rise due to the increasing adoption of companion animals, which are more susceptible to fungi-related illnesses like coccidiosis.

The American Pet Products Association (APPA) conducted the National Pet Owners Survey of 2021-2022, revealing this trend.

Pet owners are increasing in Canada and Mexico, with 38% of Canadian homes having dogs in 2021, compared to 38% with cats.

Additionally, 17% of Canadian pet owners are spending more money on their animals, with 17% willing to pay over $500 annually for veterinary treatment.

The Asia-Pacific market dominates due to increased chicken farming, media campaigns, and healthcare infrastructure. The report also highlights market-impacting variables and domestic regulatory changes, affecting present and future trends in the region.

Segments Covered in the Anticoccidial Drugs Market Report

Anticoccidial Drugs Market Segment by Drug Type

• Ionophore
• Antibiotic
• Sulphonamides
• Chemical Derivative
• and Others

Anticoccidial Drugs Market by Drug Action

• Coccidiostatic
• Coccidiocidal

Anticoccidial Drugs Market by Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Australia
  • Rest of Asia-Pacific
• Rest of the World
• Middle East
• Africa
• Latin America

Frequently Asked Questions

What does Anticoccidial Drugs do?

Anticoccidial pharmaceuticals: Anticoccidial drugs are medications used to treat and prevent coccidia infections. Agents that eradicate the coccidial population are referred to as coccidiocidal, whereas those that stop the coccidial population from reproducing and expanding are called coccidiostatic.

 What is the expected growth rate of the Anticoccidial Drugs market over the next 7 years?

The Anticoccidial Drugs Market to grow from USD 1.42 Billion in 2023 to USD 1.97 Billion by 2030, at a CAGR of 3.6%

Who are the major players in the Anticoccidial Drugs market and what is their market share?

Boehringer Ingelheim, Ceva, Elanco Animal Health, Merck, Virbac, and Zoetis, are prominent players operating and dominating in the market.

Which geographical areas dominate the worldwide market for Anticoccidial Drugs?

North America region are emerging as the top regional markets for Anticoccidial Drugs.